This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Vaccination was a seven-valent pneumococcal conjugate vaccine administered in three doses (at two, four, and six months old) and this was compared with no vaccination.
Location/setting
Latin America and the Caribbean (45 countries)/primary care.
Methods

Analytical approach:
The analysis was based on a decision analytic model and the horizon seemed to be a lifetime. The authors stated that a societal perspective was adopted, with a secondary analysis from the perspective of the health care system.
Effectiveness data:
Most of the clinical and epidemiological data were from a systematic review of published and unpublished literature; the methods of this review were published elsewhere. Other data were from selected sources. Vaccine efficacy was a key model input and was from a clinical trial carried out in Northern California by Kaiser Permanente. The data from studies conducted outside Latin America and the Caribbean were adjusted to the specific characteristics of this area.
Monetary benefit and utility valuations:
The disability weights were from a published source, but its details were not given.
Measure of benefit:
Disability-adjusted life-years (DALYs) were the summary benefit measure and they were discounted at an annual rate of 3%. Other model outputs, such as cases of acute otitis media, pneumonia, and pneumococcal disease, were also reported.
Cost data:
The economic analysis included the costs of vaccination (acquisition, administration, and losses from waste), treatment of pneumococcal disease (hospital stay, personnel time, out-patient visits, diagnostic tests, and medications), and nonmedical items (transport and parent or carer time). The vaccine price was not available for Latin America and the
